Literature DB >> 24613518

The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol.

Robin P F Dullaart1, Wijtske Annema2, René A Tio3, Uwe J F Tietge2.   

Abstract

BACKGROUND: Intrinsic functional properties of high density lipoproteins (HDL) are considered to be physiologically important for atheroprotection. We compared the HDL anti-inflammatory capacity between patients with acute myocardial infarction (MI) and patients with non-cardiac chest pain, and prospectively determined the association of new major adverse cardiovascular events (MACE) with this metric of HDL function.
METHODS: A prospective study was carried out in 93 patients referred for acute chest pain (65 patients with acute MI). The HDL anti-inflammatory capacity was determined as the ability to suppress tumor necrosis factor-α-induced vascular cell adhesion molecule-1 mRNA expression in endothelial cells in vitro.
RESULTS: Acute MI at admission was associated with impaired HDL anti-inflammatory capacity (p=0.001), even after adjustment for HDL cholesterol and apolipoprotein A-I (p=0.003). Twenty nine MACE were ascertained during a median follow-up of 1210 (910-1679) days. New MACE was associated with impaired HDL anti-inflammatory capacity (hazard ratio: 1.80 (1.17-2.77) per SD change, p=0.007) in age, sex, HDL cholesterol and apolipoprotein-AI adjusted analysis.
CONCLUSIONS: The ability of HDL to attenuate endothelial inflammation is impaired in acute MI, and this metric of HDL function may serve as a predictor of new MACE, even independent of HDL cholesterol and apolipoprotein A-I.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Atypical chest pain; HDL anti-inflammatory function; Non-STEMI; STEMI

Mesh:

Substances:

Year:  2014        PMID: 24613518     DOI: 10.1016/j.cca.2014.02.026

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.

Authors:  Emily Bowman; Nicholas T Funderburg
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

2.  Anti-inflammatory function of apolipoprotein B-depleted plasma is impaired in non-alcoholic fatty liver disease.

Authors:  Negar Sarmadi; Hossein Poustchi; Fatemeh Ali Yari; Amir Reza Radmard; Sara Karami; Abbas Pakdel; Parisa Shabani; Ali Khaleghian
Journal:  PLoS One       Date:  2022-04-12       Impact factor: 3.240

Review 3.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

4.  The Monitoring of Protein Markers of Inflammation and Serum Lipid Concentration in Obese Subjects with Metabolic Syndrome.

Authors:  Dragana Puhalo Sladoje; Bojana Kisić; Dijana Mirić
Journal:  J Med Biochem       Date:  2017-10-28       Impact factor: 3.402

5.  Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes.

Authors:  Christina E Kostara; Eleuterio Ferrannini; Eleni T Bairaktari; Athanasios Papathanasiou; Moses Elisaf; Vasilis Tsimihodimos
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

6.  Metabolic Syndrome in an Aging Society - Role of Oxidant-Antioxidant Imbalance and Inflammation Markers in Disentangling Atherosclerosis.

Authors:  Sylwia Dziegielewska-Gesiak
Journal:  Clin Interv Aging       Date:  2021-06-09       Impact factor: 4.458

7.  Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.

Authors:  Aleksandra Kimak; Małgorzata Strycharz-Dudziak; Teresa Bachanek; Elżbieta Kimak
Journal:  Lipids Health Dis       Date:  2015-12-14       Impact factor: 3.876

8.  Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.

Authors:  Ruben N Eppinga; Minke H T Hartman; Dirk J van Veldhuisen; Chris P H Lexis; Margery A Connelly; Erik Lipsic; Iwan C C van der Horst; Pim van der Harst; Robin P F Dullaart
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

9.  The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation.

Authors:  Sanam Ebtehaj; Eke G Gruppen; Mojtaba Parvizi; Uwe J F Tietge; Robin P F Dullaart
Journal:  Cardiovasc Diabetol       Date:  2017-10-12       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.